Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2010

Silver Daniel P, Richardson Andrea L, Eklund Aron C, Wang Zhigang C, Szallasi Zoltan, Li Qiyuan, Juul Nicolai, Leong Chee-Onn, Calogrias Diana, Buraimoh Ayodele, Fatima Aquila, Gelman Rebecca S, Ryan Paula D, Tung Nadine M, De Nicolo Arcangela, Ganesan Shridar, Miron Alexander, Colin Christian, Sgroi Dennis C, Ellisen Leif W, Winer Eric P, Garber Judy E

Abstract excerpt

PURPOSE Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-mutated breast cancers. Because sporadic triple-negative breast cancer (TNBC) and BRCA1-associated breast cancer sh...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Neoadjuvant Therapy

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Tumor Protein p73

Source

Open in PubMed Open full text

Identifiers

PMID: 20100965
DOI: 10.1200/JCO.2009.22.4725
PMCID: PMC2834466

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20100965-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.PMID 20100965Read ↗

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity Read ↗

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.Semantic proximity Read ↗

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Semantic proximity Read ↗

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.Semantic proximity Read ↗

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.Semantic proximity Read ↗

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesSemantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.Semantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

The triple-negative subtype: new ideas for the poorest prognosis breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.